Comparative clinical and economic evaluation of phosphocreatine (Neoton) administration during cardiac surgery with extracorporeal ciculation

Download in PDF

Aim

Clinical and aconomic evaluation of phosphocreatine (Neoton) administration during cardiac surgery with extracorporeal ciculation.

Material and methods

Modelling was used to evaluate cost-effectiveness and budget impact of phosphocreatine and levosimendan administration during cardiac surgey. Efficacy of two medication was compared by network meta-analysis.

Results

Perioperative phosphocreatine administration during extracorporeal circulation results in a lower risk of unfavorable outcomes including myocardial infarction, serious arrhythmias and inotropic requirement compared to the standard treatment, and is 42.8% cheaper compared to levosimendan administration.

Conclusion

Phosphocreatine administration during cardiac surgery is cost saving and more effective that levosimendan administration.

Key words

Pharmacoeconomics, budget impact analysis, cardiac protection, cardiac surgery, phosphocreatine.